Regulus Therapeutics
RGLS
$2.78
Share price
-0.71%
Change (1 day)
127.87%
Change (1 year)
Categories
P/S ratio for Regulus Therapeutics (RGLS)
P/S ratio as of April 2024 (TTM): N/A
According to Regulus Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2023 the company had a P/S ratio of N/A.
P/S ratio history for Regulus Therapeutics from 2012 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | N/A | |
| 2022 | N/A | |
| 2021 | N/A | -100% |
| 2020 | 8.57 | 212.92% |
| 2019 | 2.74 | -97.6% |
| 2018 | 114 | -92.41% |
| 2017 | > 1000 | 1405.64% |
| 2016 | 99.7 | 350.77% |
| 2015 | 22.1 | -78.39% |
| 2014 | 102 | 548.71% |
| 2013 | 15.8 | -11.22% |
| 2012 | 17.8 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | 2.32 | N/A | 🇫🇷 France |
 Biogen BIIB | 2.91 | N/A | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 2.18 | N/A | 🇺🇸 USA |
 AstraZeneca AZN | 4.65 | N/A | 🇬🇧 UK |
 GlaxoSmithKline GSK | 2.20 | N/A | 🇬🇧 UK |
 Sangamo Therapeutics
SGMO | 0.6415 | N/A | 🇺🇸 USA |
 Dicerna Pharmaceuticals DRNA | N/A | N/A | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | 10.2 | N/A | 🇺🇸 USA |